In conclusion, our findings highlight that elevated VPS25 expression serves as a strong predictor of unfavorable clinical outcomes in HNSCC, warranting further investigation into its role in tumor progression and potential therapeutic targeting. This evidence concerns the gene VPS25 and head and neck squamous cell carcinoma.